Review



rabbit anti mcm10  (Bethyl)


Bioz Verified Symbol Bethyl is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Bethyl rabbit anti mcm10
    Rabbit Anti Mcm10, supplied by Bethyl, used in various techniques. Bioz Stars score: 92/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+mcm10/pmc12583452-60-0-3?v=Bethyl
    Average 92 stars, based on 17 article reviews
    rabbit anti mcm10 - by Bioz Stars, 2026-08
    92/100 stars

    Images



    Similar Products

    rabbit anti mcm10  (Bethyl)
    92
    Bethyl rabbit anti mcm10
    Rabbit Anti Mcm10, supplied by Bethyl, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+mcm10/pmc12583452-60-0-3?v=Bethyl
    Average 92 stars, based on 1 article reviews
    rabbit anti mcm10 - by Bioz Stars, 2026-08
    92/100 stars
    		  Buy from Supplier
    rabbit anti human mcm10 antibody  (Proteintech)
    93
    Proteintech rabbit anti human mcm10 antibody
    A GSVA of the risk score cohorts. Differentially expressed pathways were identified using GSVA through hallmark gene sets. B Scatterplot showing the top eight Pearson correlations between mRNAsi scores and the model genes in TCGA-HCC patients. C Gene set enrichment analysis (GSEA) with high and low <t>MCM10</t> expression. The stemness-associated and drug-resistance-related sets enriched high MCM10 expression, including the E2F-targets, PI3K-AKT-MTOR signaling, are shown. D , E Western blots showing expression levels of total and phosphorylated AKT, PI3K, S6K1, and 4EBP1 proteins in MCM10‐overexpressed HepG2(D), MCM10‐knockout HepG2-SR(E), and control cells. P < 0.05, FDR < 0.25.
    Rabbit Anti Human Mcm10 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+mcm10/pmc12535913-75-8-19?v=Proteintech
    Average 93 stars, based on 1 article reviews
    rabbit anti human mcm10 antibody - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    rabbit anti mcm10  (Novus Biologicals)
    92
    Novus Biologicals rabbit anti mcm10
    A GSVA of the risk score cohorts. Differentially expressed pathways were identified using GSVA through hallmark gene sets. B Scatterplot showing the top eight Pearson correlations between mRNAsi scores and the model genes in TCGA-HCC patients. C Gene set enrichment analysis (GSEA) with high and low <t>MCM10</t> expression. The stemness-associated and drug-resistance-related sets enriched high MCM10 expression, including the E2F-targets, PI3K-AKT-MTOR signaling, are shown. D , E Western blots showing expression levels of total and phosphorylated AKT, PI3K, S6K1, and 4EBP1 proteins in MCM10‐overexpressed HepG2(D), MCM10‐knockout HepG2-SR(E), and control cells. P < 0.05, FDR < 0.25.
    Rabbit Anti Mcm10, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+mcm10/pm38262603-362-11-13?v=Novus+Biologicals
    Average 92 stars, based on 1 article reviews
    rabbit anti mcm10 - by Bioz Stars, 2026-08
    92/100 stars
    		  Buy from Supplier
    rabbit anti mcm10  (Proteintech)
    93
    Proteintech rabbit anti mcm10
    A GSVA of the risk score cohorts. Differentially expressed pathways were identified using GSVA through hallmark gene sets. B Scatterplot showing the top eight Pearson correlations between mRNAsi scores and the model genes in TCGA-HCC patients. C Gene set enrichment analysis (GSEA) with high and low <t>MCM10</t> expression. The stemness-associated and drug-resistance-related sets enriched high MCM10 expression, including the E2F-targets, PI3K-AKT-MTOR signaling, are shown. D , E Western blots showing expression levels of total and phosphorylated AKT, PI3K, S6K1, and 4EBP1 proteins in MCM10‐overexpressed HepG2(D), MCM10‐knockout HepG2-SR(E), and control cells. P < 0.05, FDR < 0.25.
    Rabbit Anti Mcm10, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+mcm10/pmc09737295-251-4-9?v=Proteintech
    Average 93 stars, based on 1 article reviews
    rabbit anti mcm10 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    rabbit polyclonal antibody against mcm10  (Danaher Inc)
    99
    Danaher Inc rabbit polyclonal antibody against mcm10
    A GSVA of the risk score cohorts. Differentially expressed pathways were identified using GSVA through hallmark gene sets. B Scatterplot showing the top eight Pearson correlations between mRNAsi scores and the model genes in TCGA-HCC patients. C Gene set enrichment analysis (GSEA) with high and low <t>MCM10</t> expression. The stemness-associated and drug-resistance-related sets enriched high MCM10 expression, including the E2F-targets, PI3K-AKT-MTOR signaling, are shown. D , E Western blots showing expression levels of total and phosphorylated AKT, PI3K, S6K1, and 4EBP1 proteins in MCM10‐overexpressed HepG2(D), MCM10‐knockout HepG2-SR(E), and control cells. P < 0.05, FDR < 0.25.
    Rabbit Polyclonal Antibody Against Mcm10, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+mcm10/pm32030558-37-14-19?v=Danaher+Inc
    Average 99 stars, based on 1 article reviews
    rabbit polyclonal antibody against mcm10 - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    A GSVA of the risk score cohorts. Differentially expressed pathways were identified using GSVA through hallmark gene sets. B Scatterplot showing the top eight Pearson correlations between mRNAsi scores and the model genes in TCGA-HCC patients. C Gene set enrichment analysis (GSEA) with high and low MCM10 expression. The stemness-associated and drug-resistance-related sets enriched high MCM10 expression, including the E2F-targets, PI3K-AKT-MTOR signaling, are shown. D , E Western blots showing expression levels of total and phosphorylated AKT, PI3K, S6K1, and 4EBP1 proteins in MCM10‐overexpressed HepG2(D), MCM10‐knockout HepG2-SR(E), and control cells. P < 0.05, FDR < 0.25.

    Journal: Cancer Gene Therapy

    Article Title: Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma

    doi: 10.1038/s41417-025-00946-0

    Figure Lengend Snippet: A GSVA of the risk score cohorts. Differentially expressed pathways were identified using GSVA through hallmark gene sets. B Scatterplot showing the top eight Pearson correlations between mRNAsi scores and the model genes in TCGA-HCC patients. C Gene set enrichment analysis (GSEA) with high and low MCM10 expression. The stemness-associated and drug-resistance-related sets enriched high MCM10 expression, including the E2F-targets, PI3K-AKT-MTOR signaling, are shown. D , E Western blots showing expression levels of total and phosphorylated AKT, PI3K, S6K1, and 4EBP1 proteins in MCM10‐overexpressed HepG2(D), MCM10‐knockout HepG2-SR(E), and control cells. P < 0.05, FDR < 0.25.

    Article Snippet: The western blot analysis utilized the following antibodies: rabbit anti-human MCM10 antibody (#DF12162, Affinity), rabbit anti-human KLF4 antibody (#11880-1-AP, Proteintech), rabbit anti-human SOX2 antibody (#A0561, Abclonal), mouse monoclonal anti-human AKT antibody (#YM3618, Immunoway), rabbit anti-human p-AKT antibody (#YM8304, Immunoway), mouse monoclonal anti-human PI3K antibody (#60225, Proteintech), rabbit anti-human p-PI3K antibody (#AF3242, Affinity), rabbit anti-human S6K1 antibody (#380469, Immunoway), rabbit anti-human p-S6K1 antibody (#310310, Immunoway), rabbit anti-human 4EBP1 antibody (# R24197 , Immunoway), rabbit anti-human p-4EBP1 antibody (# R22929 , Immunoway) and mouse monoclonal anti-human β-actin antibody (#AF7018, Affinity).

    Techniques: Expressing, Western Blot, Knock-Out, Control

    A Immunohistochemical analysis illustrating the positive correlation between MCM10 expression and key stemness markers (KLF4, SOX2) in hepatocellular carcinoma cells. B Western blots results showed that KLF4 and SOX2 expression levels were consistent with MCM10 expression in HepG2 cells. C Tumor sphere formation results showed stable overexpression or knockout of MCM10 affects HepG2 cell stemness. D Immunofluorescence was examined for fluorescence intensity and CD44 and CD133 colocalization in HepG2 cells. E Flow cytometry results illustrate that the expression level of MCM10 affects the number of CD133 + cells. The asterisks represented the statistical p-value (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

    Journal: Cancer Gene Therapy

    Article Title: Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma

    doi: 10.1038/s41417-025-00946-0

    Figure Lengend Snippet: A Immunohistochemical analysis illustrating the positive correlation between MCM10 expression and key stemness markers (KLF4, SOX2) in hepatocellular carcinoma cells. B Western blots results showed that KLF4 and SOX2 expression levels were consistent with MCM10 expression in HepG2 cells. C Tumor sphere formation results showed stable overexpression or knockout of MCM10 affects HepG2 cell stemness. D Immunofluorescence was examined for fluorescence intensity and CD44 and CD133 colocalization in HepG2 cells. E Flow cytometry results illustrate that the expression level of MCM10 affects the number of CD133 + cells. The asterisks represented the statistical p-value (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

    Article Snippet: The western blot analysis utilized the following antibodies: rabbit anti-human MCM10 antibody (#DF12162, Affinity), rabbit anti-human KLF4 antibody (#11880-1-AP, Proteintech), rabbit anti-human SOX2 antibody (#A0561, Abclonal), mouse monoclonal anti-human AKT antibody (#YM3618, Immunoway), rabbit anti-human p-AKT antibody (#YM8304, Immunoway), mouse monoclonal anti-human PI3K antibody (#60225, Proteintech), rabbit anti-human p-PI3K antibody (#AF3242, Affinity), rabbit anti-human S6K1 antibody (#380469, Immunoway), rabbit anti-human p-S6K1 antibody (#310310, Immunoway), rabbit anti-human 4EBP1 antibody (# R24197 , Immunoway), rabbit anti-human p-4EBP1 antibody (# R22929 , Immunoway) and mouse monoclonal anti-human β-actin antibody (#AF7018, Affinity).

    Techniques: Immunohistochemical staining, Expressing, Western Blot, Over Expression, Knock-Out, Immunofluorescence, Fluorescence, Flow Cytometry

    A Kaplan-Meier survival curves displaying the relationship between high MCM10 expression and decreased survival rates in hepatocellular carcinoma patients. B Weight changes of nude mice after subcutaneous injections of HepG2-Vector/oeMCM10 and HepG2-SR-Ctrl/MCM10 KO cells in nude mice. C Growth curves of transplanted tumors after HCC cells injection. The transplanted tumors ( D ) and their weights ( E ) were obtained 40 days after HCC cells subcutaneous injection. F Paraffin-embedded sections of xenograft tumors were stained by H&E and immunohistochemistry (IHC) using MCM10, KLF4, SOX2, and Ki67 antibodies. The asterisks represented the statistical p-value (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

    Journal: Cancer Gene Therapy

    Article Title: Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma

    doi: 10.1038/s41417-025-00946-0

    Figure Lengend Snippet: A Kaplan-Meier survival curves displaying the relationship between high MCM10 expression and decreased survival rates in hepatocellular carcinoma patients. B Weight changes of nude mice after subcutaneous injections of HepG2-Vector/oeMCM10 and HepG2-SR-Ctrl/MCM10 KO cells in nude mice. C Growth curves of transplanted tumors after HCC cells injection. The transplanted tumors ( D ) and their weights ( E ) were obtained 40 days after HCC cells subcutaneous injection. F Paraffin-embedded sections of xenograft tumors were stained by H&E and immunohistochemistry (IHC) using MCM10, KLF4, SOX2, and Ki67 antibodies. The asterisks represented the statistical p-value (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

    Article Snippet: The western blot analysis utilized the following antibodies: rabbit anti-human MCM10 antibody (#DF12162, Affinity), rabbit anti-human KLF4 antibody (#11880-1-AP, Proteintech), rabbit anti-human SOX2 antibody (#A0561, Abclonal), mouse monoclonal anti-human AKT antibody (#YM3618, Immunoway), rabbit anti-human p-AKT antibody (#YM8304, Immunoway), mouse monoclonal anti-human PI3K antibody (#60225, Proteintech), rabbit anti-human p-PI3K antibody (#AF3242, Affinity), rabbit anti-human S6K1 antibody (#380469, Immunoway), rabbit anti-human p-S6K1 antibody (#310310, Immunoway), rabbit anti-human 4EBP1 antibody (# R24197 , Immunoway), rabbit anti-human p-4EBP1 antibody (# R22929 , Immunoway) and mouse monoclonal anti-human β-actin antibody (#AF7018, Affinity).

    Techniques: Expressing, Plasmid Preparation, Injection, Staining, Immunohistochemistry

    A Connectivity Map (CMap) analysis identified TW-37 as a potential inhibitor impacting the expression profiles of HepG2 and Hep3B sorafenib-resistant (SR) cell lines. B CCK8 was conducted to determine the half maximal inhibitory concentration (IC50) of TW-37 in HepG2-SR and Hep3B-SR cell lines. C Western blot analysis assessed the time-dependent effects of 50 µM TW-37 on MCM10, KLF4, and SOX2 protein levels in HepG2-SR and Hep3B-SR cells over 48 h. D Dose-dependent effects of TW-37 on the expression levels of the stemness markers were analyzed after 48 h of treatment in HepG2-SR and Hep3B-SR cell lines. E Effects of TW-37 and sorafenib on HepG2-SR and Hep3B-SR cell viability were quantified with CCK8 assays. F Cell viability was assessed in CCK8 assays after treatment of HepG2-SR and Hep3B-SR with Sorafenib alone, TW-37, or a two-drug combination time gradient. No significance (NS) was observed in specific pairings. The asterisks represented the statistical p-value (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

    Journal: Cancer Gene Therapy

    Article Title: Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma

    doi: 10.1038/s41417-025-00946-0

    Figure Lengend Snippet: A Connectivity Map (CMap) analysis identified TW-37 as a potential inhibitor impacting the expression profiles of HepG2 and Hep3B sorafenib-resistant (SR) cell lines. B CCK8 was conducted to determine the half maximal inhibitory concentration (IC50) of TW-37 in HepG2-SR and Hep3B-SR cell lines. C Western blot analysis assessed the time-dependent effects of 50 µM TW-37 on MCM10, KLF4, and SOX2 protein levels in HepG2-SR and Hep3B-SR cells over 48 h. D Dose-dependent effects of TW-37 on the expression levels of the stemness markers were analyzed after 48 h of treatment in HepG2-SR and Hep3B-SR cell lines. E Effects of TW-37 and sorafenib on HepG2-SR and Hep3B-SR cell viability were quantified with CCK8 assays. F Cell viability was assessed in CCK8 assays after treatment of HepG2-SR and Hep3B-SR with Sorafenib alone, TW-37, or a two-drug combination time gradient. No significance (NS) was observed in specific pairings. The asterisks represented the statistical p-value (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

    Article Snippet: The western blot analysis utilized the following antibodies: rabbit anti-human MCM10 antibody (#DF12162, Affinity), rabbit anti-human KLF4 antibody (#11880-1-AP, Proteintech), rabbit anti-human SOX2 antibody (#A0561, Abclonal), mouse monoclonal anti-human AKT antibody (#YM3618, Immunoway), rabbit anti-human p-AKT antibody (#YM8304, Immunoway), mouse monoclonal anti-human PI3K antibody (#60225, Proteintech), rabbit anti-human p-PI3K antibody (#AF3242, Affinity), rabbit anti-human S6K1 antibody (#380469, Immunoway), rabbit anti-human p-S6K1 antibody (#310310, Immunoway), rabbit anti-human 4EBP1 antibody (# R24197 , Immunoway), rabbit anti-human p-4EBP1 antibody (# R22929 , Immunoway) and mouse monoclonal anti-human β-actin antibody (#AF7018, Affinity).

    Techniques: Expressing, Concentration Assay, Western Blot